Calamos Advisors LLC Ligand Pharmaceuticals Inc Transaction History

Calamos Advisors LLC

$15.7 Billion
Q1 2025

A detailed history of Calamos Advisors LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Calamos Advisors LLC holds 19,934 shares of LGND stock, worth $2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

19,934

Previous 14,415 38.29%

Holding current value

$2 Million

Previous $1.54 Million 35.69%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 28, 2025	BUY	$105.14 - $122.23 $580,267 - $674,587	5,519 Added 38.29%	19,934 $2.1 Million
Q4 2024 Jan 24, 2025	SELL	$99.95 - $129.9 $4,897 - $6,365	-49 Reduced 0.34%	14,415 $1.54 Million
Q3 2024 Nov 07, 2024	BUY	$82.7 - $110.11 $299,125 - $398,267	3,617 Added 33.35%	14,464 $1.45 Million
Q2 2024 Jul 25, 2024	BUY	$68.53 - $87.91 $124,176 - $159,292	1,812 Added 20.06%	10,847 $913,000
Q1 2024 May 08, 2024	BUY	$68.64 - $89.2 $305,379 - $396,850	4,449 Added 97.01%	9,035 $660,000
Q4 2023 Jan 31, 2024	BUY	$49.57 - $72.63 $227,328 - $333,081	4,586 New	4,586 $327,000
Q2 2023 Jul 28, 2023	SELL	$69.53 - $79.33 $770,183 - $878,738	-11,077 Reduced 46.75%	12,619 $909,000
Q1 2023 May 03, 2023	BUY	$65.67 - $77.08 $510,518 - $599,219	7,774 Added 48.83%	23,696 $1.74 Million
Q4 2022 Jan 25, 2023	BUY	$61.72 - $96.74 $982,705 - $1.54 Million	15,922 New	15,922 $0
Q1 2019 Apr 12, 2019	SELL	$105.93 - $142.47 $162,072 - $217,979	-1,530 Closed	0 $0
Q3 2018 Oct 22, 2018	BUY	$211.18 - $274.49 $323,105 - $419,969	1,530 New	1,530 $420,000

Others Institutions Holding LGND

# of Institutions

280

Shares Held

19M

Call Options Held

9.5K

Put Options Held

8.1K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.69B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.

Account

Calamos Advisors LLC Ligand Pharmaceuticals Inc Transaction History